2022年12月19日

2022年12月19日,加州拉霍亚(业务线)- Enlaza疗法,第一个共价生物平台公司,今天宣布正式启动与关闭6100万美元的种子资金。融资是由阿瓦隆企业和光速创投,加入了弗雷泽生命科学,轮回BioCapital。融资将用于进一步推进Enlaza专有的术士平台和建立一个管道的共价生物制剂,最初重点发展小说,分化癌症治疗目标有效性和低毒性。“我们结合最近的突破,允许引入专有的非自然氨基酸蛋白质药物,使特定的目标蛋白质共价结合,”塞吉奥毒龙说,博士,首席执行官Enlaza疗法。“我们的共价生物平台是白色空间技术,我们正在开拓一个全新的类生物疗法的潜力显著提高疗效和安全性,解决众多迹象和疾病领域。”“Enlaza建造了一个高度分化治疗平台,首次将使共价生物制剂,”杰里胥特博士说,阿瓦隆公司的管理合伙人。“平台提供的机会开发药物对多个目标类,所有治疗领域提供了机遇。“巫师平台创造了非常具体的治疗弹头,锁定目标,生产广泛适用的治疗候选人的药物类属性。例如,蛋白质药物来源于平台可以修改,可以把各种载荷,产生抗体药物配合(adc)或放射性配体疗法(RLTs)与特定的目标组织发货,不需要半衰期延长工程。Enlaza候选人产生了其肿瘤药物临床前数据显示肿瘤快速渗透加上高系统性间隙,高肿瘤保留,和不相干的毒性较低。“Enlaza广度的平台将跨多个模式变革,“雪莱Chu说,医学博士光速创投。博士,合伙人 Marcos Milla, Ph.D., Venture Partner at Samsara BioCapital said, “The Enlaza platform opens the possibility to enhance the therapeutic index of biologic drugs in a way that is not accessible with platforms relying on conventional recombinant technologies. It also offers an opportunity to address hard to target cell surface molecules in a highly specific fashion.” “We are impressed with the in vitro and in vivo data the team has generated and believe that Enlaza can build an industry leading pipeline of important new protein drugs employing its incomparable technological advantage,” said Jamie Topper, M.D., Ph.D., Managing Partner of Frazier Life Sciences. In addition to Dr. Duron, Enlaza’s leadership team includes Sanford (Sandy) Madigan, Ph.D., President and Chief Business Officer, Analeah Heidt, Ph.D., Chief Scientific Officer, and Lei Wang Ph.D., Scientific Advisor and Professor at the University of California, San Francisco (UCSF). The company’s Board of Directors is comprised of Jay Lichter, Ph.D. Avalon Ventures; Jamie Topper, M.D., Ph.D., Frazier Life Sciences, Shelley Chu, M.D., Ph.D., Lightspeed Venture Partners, Marcos Milla, Ph.D., Samsara BioCapital, and Sergio Duron, Ph.D., CEO, Enlaza Therapeutics. Enlaza’s War-Lock platform is based on technologies exclusively licensed from UCSF, negotiated through UCSF’s Innovation Ventures’ Office of Technology Management & Advancement, which leads licensing and business development efforts on behalf of the University, and The Scripps Research Institute. About Enlaza Therapeutics Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-LockTM platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics. For more information, please visit www.enlazatx.com .